The Miami criteria were developed and validated to standardize definitions of dysplasia and cancer during probe-based confocal laser endomicroscopy (pCLE) of Barrett's esophagus. These criteria do not distinguish high-grade dysplasia from low-grade dysplasia (LGD). The aim of our study was to evaluate the accuracy of Miami criteria for LGD in Barrett's esophagus. Methods: We reviewed medical records of all patients undergoing pCLE for Barrett's esophagus from December 2014 to December 2016. An expert pathologist performed blinded review of histology specimens. Patients with LGD on blinded or un-blinded pathology review were included. Patients with nondysplastic Barrett's (NDB) on blinded and un-blinded pathology review were randomly included in a 1:1 ratio as a control group. Two gastroenterologists with expertise in pCLE blindly interpreted all pCLE sequences based solely on Miami criteria and independently assigned a diagnosis as well as degree of confidence. Results: 20 patients with LGD and 20 patients with NDB were included. Patients with LGD had a significantly longer median Barrett's segment than those with NDB (5 cm vs. 2 cm, P=0.003). Inter-observer agreement was poor between blinded and un-blinded pathologists (kappa=0.2), but substantial between the two blinded pCLE reviewers (kappa=0.78). Among the 4 patients with LGD on both blinded and un-blinded pathology review, Miami criteria for LGD were felt to be satisfied in 3 patients by one pCLE reviewer, and 2 patients by the second pCLE reviewer. In the 20 patients with LGD identified by at least one pathologist, accuracy of pCLE Miami criteria were as follows: sensitivity 35-50%, specificity 70-75%, positive predictive value 58-63%, and negative predictive value 54 to 58% (Tables 1 and 2 ). Among the 20 patients with NDB on blinded and un-blinded pathology review, both pCLE reviewers identified dysplasia in 5 patients.
[417] A. pCLE image demonstrates villiform structures with dark irregularly thickened epithelial borders; B. Corresponding histology image at 40X magnification shows relatively preserved architecture with elongated, crowded hyperchromatic nuclei and loss of nuclear polarity.
[417_A] Overall agreement between pCLE reviewer #1 and pathologists
LGD blinded or un-blinded pathology (n=20)
NDB blinded and un-blinded pathology (n=20)
LGD pCLE reviewer #1 7 5
NDB pCLE reviewer #1 13 15
LGD Low grade dysplasia; NDB non-dysplastic Barretts.
[417_B] Overall agreement between pCLE reviewer #2 and pathologists
LGD blinded or un-blinded pathology (n=20) NDB blinded and un-blinded pathology (n=20)
LGD pCLE reviewer #2 10 6 NDB pCLE reviewer #2 10 14
Introduction: There has been an ongoing debate on the relevance of breath testing (BT) in identifying small intestinal bacterial overgrowth (SIBO), especially in subjects with irritable bowel syndrome (IBS). Although the nonsystemic antibiotic rifaximin is approved for the treatment of IBS with diarrhea (IBS-D) in adults, determinants of response remain unclear. In this analysis, we examined the potential utility of BT in predicting response to rifaximin treatment.
Methods:
As part of the previously published TARGET 3 trial, 1 home kits were used to conduct lactulose breath testing in a subset of patients with IBS-D. Subjects had a breath test at baseline, after completion of a 2-week course of open-label rifaximin 550 mg twice daily, after relapse (retreatment baseline), and after subsequent retreatment with rifaximin. Breath test results were categorized as positive or negative based on the 2017 North American Consensus publication. 2 These results were then compared, based on patient response to rifaximin (FDA-defined composite endpoint). Response was defined as meeting weekly response for abdominal pain (≥30% decrease from baseline in mean weekly pain score) and stool consistency (≥50% decrease from baseline in number of days/week with Bristol Stool Scale type 6 or 7 stool) during ≥2 of the first 4 weeks after treatment.
Results: Of 98 subjects enrolled in the substudy, 93 had interpretable breath tests without missing values. SIBO was detected in 66.7% of subjects prior to treatment with rifaximin. There was no significant difference in demographics or symptom profile of patients with or without SIBO (Table) . Baseline demographics and symptoms did not predict response to open-label rifaximin; however, 59.7% of patients with IBS-D and a positive baseline BT responded to rifaximin vs 25.8% of patients with a negative BT (P=0.002; odds ratio 4.3, 95% CI, 1.5-12.7). BT after rifaximin therapy did not predict response (P=0.2); however, response rate in patients whose breath test results normalized after rifaximin treatment was 76.5%. Pre-/post-rifaximin BT did not predict the time to recurrence in patients (P=0.5).
Conclusion:
A positive lactulose breath test predicted a higher likelihood of response to rifaximin in patients with IBS-D. These results point to a gut microbiome-related mechanism of action for rifaximin and the utility of breath testing in IBS. 1. Lembo A, et al. Gastroenterology. 2016; 151(6) Average daily BSS score, mean±SD 5.6±0.9 5.7±0.9 5.5±0.9 5.6±0.9 5.7±0.9
Stool frequency per day, mean±SD 3.5±1.9 3.5±1.9 3.5±1.8 3.5±1.9 3.5±1.8
Days per week with urgency, mean±SD 6.0±1.7 6.5±0.9 5.8±1.9 5.7±1.8 6.2±1.5
Average daily IBS symptoms score, mean±SD 4.3±0.9 4.2±0.9 4.4±0.8 4.3±0.9 4.3±0.9
Average daily abdominal pain score, mean±SD 5.4±1. 
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Risk of Addiction For IBS Patients Prescribed Anxiolytics: A Community-Based Study
Douglas Jay Sprung, MD. The Gastroenterology Group, Maitland, FL
Introduction: To evaluate if the prevailing perception over the past decades that anxiolytics lead to or have a significant risk for addiction, or in some other way are deleterious to patients (pts) in our community setting, is a valid and worthy concern. Methods: A retrospective study of adult Irritable bowel syndrome (IBS) pts seen between 6/2012-1/2017 was undertaken, from our community based gastroenterology practice in Orlando, Florida. We culled out those with IBS and general anxiety state (GAS), and those with IBS and non-cardiac chest pain (NCCP). A follow up period of >3 months was required. All insurances except Medicaid and certain HMO's were accepted. Use of anxiolytics had to begin during the study period. A minimum of 3 follow up visits were required. All patients studied were on an anticholinergics (hyoscyamine, dicyclomine, donnatal), but a few were on lubiprostone or Linaclotide. Anxiolytics included: clonazepam, alprazolam, lorazepam and diazepam. Doses ranged from 0.125 mg bid to 0.5 mg tid and 2-5 mg bid for diazepam. Results: Of 1148 unique pts identified with IBS, 182(15%) had concomitant GAS and/or NCCP, 141/182(77%) had GAS and IBS, 41/182 (23%) had NCCP and IBS. The mean follow up was 1.5 years.
The mean age was 65 and the sex ratio was 3:1 female to male. 11 pts (6%) increased their initial anxiolytic dose during follow up, but then maintained that dose. 18(10%) decreased their dosage, due to lethargy. Many patients had to be convinced that anxiolytics were 1. not deleterious or addictive and 2. would help their primary GI ailment, and 3. that stress was an important element in their IBS and that they had stress in their lives. It often took many months of convincing before pts would commit to a treatment trial. No complications,falls,memory disorders or clinical indications of addiction were brought to our attention, other than lethargy and foggy headedness, that resolved with a lower dose.
Conclusion:
1. No clinical indication of addiction to anxiolytics was seen in our community based suburban cohort with IBS and GAS or NCCP. 2. Anxiety treatment yielded improvement in IBS and NCCP symptoms in all pts. 3. Improved quality of life on anxiolytics was observed by patient, family and physician. 4. Anxiolytics appear to be quite safe in this cohort when given in judicious doses. Perceptions of addiction need to be updated by physicians and society. 
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Impact of Stool Consistency on Bowel Movement Satisfaction in IBS-C or CIC Patients Treated With Linaclotide or Other Medications: Results From the CONTOR Study
Introduction:
Medications for constipation can cause loose or watery stools (LoWS). As new medications become available, an understanding of patients' perceptions regarding treatment effects and satisfaction may help clinicians manage patients' expectations and inform clinical perspectives of these treatments. Linaclotide is one of several treatment options for irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC); however, little information is available on the impact of stool consistency on patient-reported bowel movement (BM) satisfaction associated with their treatment options. Methods: Data were derived from CONTOR, a longitudinal research platform combining administrative claims and patient survey data for IBS-C and CIC patients [1] . Pooled data from two patient-reported 7-day daily diaries completed at baseline and Month 12 were used to create a dataset of 2907 diaries representing 26,524 BMs for 1830 patients to understand factors influencing BM satisfaction, particularly among patients taking linaclotide. Data included bowel/abdominal symptom treatments taken in the prior 24 hours, time and 1-word description of each BM, and whether the BM was satisfactory. Binary variables were created for: medication use in the past 24 hours and categorization of the BM as LoWS (based on Bristol Stool Form Scale [BSFS] 6/7), hard or lumpy stool (HoLS, based on BSFS 1/2), or neither LoWS nor HoLS. Logistic regressions between linaclotide and LoWS analyzed the relationship between BM satisfaction and treatment.
[425] .
Introduction: Post-infection irritable bowel syndrome (PI-IBS) and functional dyspepsia (PI-FD) have been reported mostly from temperate countries. In contrast, post-infection malabsorption syndrome (PI-MAS), which may mimic PI-IBS, has been reported commonly from the tropics. No report on PI-IBS excluded PI-MAS. Hence, we studied, (i) the frequency of continuing bowel dysfunction after acute gastroenteritis (AGE), (ii) predictors of its occurrence, and (iii) frequency of PI-MAS among patients with PI-IBS.
[432] Scheme for evaluation of patients with acute gastroenteritis and controls at baseline and follow-up.
patients unable to expel the balloon within normal limits (60 seconds), a plastic stool was placed around the toilet and the BET repeated. Results: Over 7 months, 36 patients were recruited. 15 patients (42%) had an initial abnormal BET. 6 patients (40%) were able to expel the balloon using the stool. The remaining 9 patients (60%) still had an abnormal BET. Maximum sphincter and rectal (resting/squeeze) pressures, duration of sustained squeeze and intrarectal pressure did not correlate with ability to expel the balloon with use of the stool. However, patients with an abnormal BET who were able to expel the balloon with use of the stool had lower residual anal pressures compared to those who were unsuccessful (48 vs 77 mmHg, P=0.04) with an average percent relaxation of 32%.
Conclusion:
We sought to assess a simple strategy to treat PFD and to find a predictor for success based on ARM metrics. 40% of patients who failed initial BET were able to expel the balloon with use of a stool. Though largely a negative study, significantly lower residual anal pressures (>20% relaxation) were seen in patients with an initial abnormal BET who were able to expel the balloon with the stool. This may be clinically relevant in patients who cannot expel the balloon but do not have a manometric diagnosis of dyssynergia. A major study limitation was the small sample size. 
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Presidential Poster Award
Houssam Halawi, MD, Priya Vijayvargiya, MD, Irene Busciglio, BS, Ibironke Oduyebo, MD, Disha Khemani, MBBS, Michael Ryks, Deborah Rhoten, Duane Burton, MHA, Lawrence A. Szarka, MD, Andres Acosta, MD, PhD, Michael Camilleri, MD, FACG. Mayo Clinic, Rochester, MN Introduction: Nausea, vomiting and opioid-induced constipation (OIC) are common adverse effects of opioid use. Naloxegol (25mg daily) is a novel peripherally active mu-opioid receptor antagonist approved for OIC. Our aim was to compare in healthy volunteers the effects on gastrointestinal and colonic transit of treatment with codeine (C), naloxegol (N), or combination (CN), compared to placebo (P).
Methods:
We conducted a randomized, double-blind, placebo-controlled, single-center, parallel-group 3-day treatment study in 72 healthy adults from southeastern MN, randomized to 1 of 4 treatment groups, all medications p.o.: 1) CP with C, 30mg qid and P q. am; 2) NP with N, 25mg q. am and P qid; 3) CN, with C 30mg qid and N 25mg q. am; and 4) PP, matching placebos qid and q. am. Participants underwent validated scintigraphy over 48 hr to measure: gastric emptying (GE) T1/2, colonic filling at 6 hours, colonic geometric center (GC) at 8, 24 and 48 hr, and ascending colon emptying (ACE) T1/2. Colonic GC refers to the weighted average of isotopic counts in the colon with 1=all counts in ascending colon and 5=all counts in stool. Analysis was by one-way analysis of variance on ranks. Data in the . As expected, C significantly retarded colonic transit and ACE T1/2. However, no significant differences in GE T1/2, colonic filling at 6 hours, or geometric center at 8 or 48 hours were found between C-treated patients and those who concomitantly received P or N.
Conclusion:
In healthy volunteers without OIC or constipation, the short-term administration of naloxegol, 25mg, tends to accelerate gastric and small bowel transit, but, at this dose, it does not appear to reverse Introduction: Gastroparesis is a chronic gastrointestinal disorder defined by delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis is thought to place a significant financial burden on the healthcare system due to high readmission rates; however, there is relatively limited information on healthcare utilization by patients with gastroparesis To evaluate healthcare utilization, diagnostic strategies and treatment options employed in the management of patients admitted with a primary diagnosis of gastroparesis Methods: A MethOD database search for consecutive patients with an admission diagnosis of gastroparesis to a large metropolitan Hospital from 1/1/2012 to 12/31/2015 was performed. We randomly selected 285 from 1292 admitted with gastroparesis as a primary or secondary diagnosis. We looked specifically at 90 patients primarily admitted with gastroparesis and collected data on sex, age, race, results of gastric emptying studies (GES) and upper GI endoscopy (EGD), as well as therapy options employed such as medications, botulinum toxin injection, gastric electrical stimulation, or surgery. We also defined the duration of hospitalization, readmission rates and the cause of gastroparesis Results: Among the 90 patients primarily admitted with gastroparesis, 71% were female, 49% Caucasian and 34% African-American and the average age was 56 years. 52% had diabetes with an average hemoglobin A1c of 7.82. 46 % carried a coexisting diagnosis of depression and/or anxiety. Gastroparesis was defined based on delayed emptying on scintigraphy in 90% (30% were on narcotics at the time of study); 17% had retained food on EGD. The mean hospitalization duration was 11 days; 30% had at least one readmission over the time span of the study for the same diagnosis; 21% had 3 or more hospitalizations for gastroparesis. The most common prokinetic agents used included metoclopramide (74%) and erythromycin (20%). 94% of patients used proton pump inhibitors. 6% had botulinum toxin injection to the pylorus, 20% had a feeding tube placed. 2% had a gastric electrical stimulator placement; 9% had surgery.
Patients admitted to this large general hospital with a primary diagnosis of gastroparesis were predominantly Caucasian middle-aged women. Diabetes was the most common etiology but almost half also carried a psychiatric diagnosis. Prolonged hospitalization times and a high readmission rate contributed to a significant impact on health care utilization.
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Fructose Malabsorption in Patients With Functional Bloating: Frequency and Predictors
Arivarasan Kulandaivelu, DM, Amarender Puri, DM, Sanjeev Sachdeva, DM. GB Pant Hospital, New Delhi, Delhi, India Introduction: Role of fructose malabsorption(FM) as a cause of Functional bloating(FB) is not adequately addressed. We aimed to study the frequency of FM in patients with functional bloating and its comparison to that in healthy controls.
Methods:
We included 70 patients with FB satisfying ROME III criteria and 35 healthy controls. Both the groups initially underwent a Glucose Hydrogen breath test(GHBT) to exclude SIBO. Subsequently both the groups underwent fructose hydrogen breath test(FHBT) to assess for FM. 25 g of fructose in 250 ml of water was used.. Persistent rise in breath hydrogen or methane >20 ppm above basal was considered diagnostic of FM. Results: In our study, 20/70(29%) patients of FB had evidence of FM compared to 1/35(3%) healthy controls(P-0.01). 51/105(48%) participants in our study had symptoms during FHBT. 16/21(76%) participants with positive FHBT had concominant symptoms. In univariate analysis, predictors of FM in patients with FB were younger age, female gender, Bristol score >4, symptoms of epigastric discomfort and mucus in stools(P<0.05). There was no significant difference among patients with FM and those without FM with respect to diet, duration of symptoms, severity of bloating, recent PPI usage, use of promotility drugs or BMI (P-0.26,P-0.69,P-0.20,P-0.07,P-0.24 and P-0.25 respectively). However in the multivariate analysis only female gender was significantly associated with a positive FHBT(P-0.02) Conclusion: More than 1/4 th of patients of FB in our study had evidence of FM compared to healthy controls and this subset of patients with FB might benefit from dietary restriction of fructose.
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Prevalence of Cannabinoid Hyperemesis Syndrome and Its Financial Burden on the Health Care Industry
Gurkaminder Sandhu, MD, John Alvarez, MD, MPH, Austin Akers, MD, Steven Smith, MD, Trace Heavener, MD, Kristen Stephenson, MD, Victoria Jaeger, DO, Dawn Sears, MD. Baylor Scott & White Health, Temple, TX Introduction: Cannabis is currently the most commonly used recreational drug behind alcohol and tobacco worldwide. There are many therapeutic properties that have been described and documented 
Introduction:
Although an increasing number of people adhere to a gluten-free diet, non-celiac gluten sensitivity remains poorly understood. Many patients not meeting the criteria for celiac disease nevertheless have intestinal and extraintestinal symptoms that they manage by avoiding gluten.
[438] The light gray bar represents the number of hospitalized patients without Celiac disease who received a gluten-free diet per year. Dark gray represents the number of hospitalized Celiac disease patients receiving gluten-free diet orders per year.
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Others may avoid gluten due to the belief that this diet confers other medical benefits. The specific medical diagnoses associated with gluten avoidance among patients without celiac disease have not been investigated. Methods: All hospitalized patients, adults and children, at Columbia University Medical Center ordered for a gluten-free diet in 2011-2016 were identified, excluding those with a documented diagnosis of celiac disease based on history, duodenal biopsy, or positive celiac disease serologies. We matched by age and gender each gluten-free patient to 2 inpatients on a regular diet. Prevalences of comorbidities including cardiovascular, gastrointestinal, neurological, and psychiatric disorders were then identified for the gluten-free patients vs. controls. We used conditional logistic regression adjusting for race, ethnicity, and insurance status to determine the odds ratio (OR) for each comorbidity of being on a gluten-free diet.
Results:
Of the 769 inpatients on a gluten-free diet, the majority (63.6%) did not have celiac disease (Fig. 1 Introduction: Dyssynergic defecation (DD) is the discoordination of pelvic floor muscles, leading to an ineffective evacuation of stool and constipation. Three components are required to diagnose DD: constipation symptoms, a dyssynergic pattern on anorectal manometry (ARM) (paradoxical increase/lack of adequate relaxation of inter-sphincter muscles), and an abnormal balloon expulsion test (BET). Although the BET is used in conjunction with ARM to diagnose DD, the results do not always agree and as a result, the utility of ARM with BET has been scrutinized for reliability in diagnosing DD. The aims of this study were: 1) to define the prevalence of abnormal BET in our cohort of patients with constipation, and 2) to identify an ARM metric that predicts an abnormal BET.
Methods:
Patients who presented for ARM in evaluation for constipation were invited to participate in the study. Those who met inclusion and exclusion criteria were invited to participate in the study. After obtaining informed consent, the subject underwent a standard protocol for 3D-high resolution ARM with BET. After completion of ARM, a lubricated balloon filled with 50 cc of warm water connected to a catheter was inserted into the rectum and the patient was asked to expel the balloon on a commode in privacy. Expulsion time of ≤ 60 seconds (s) was considered normal. Results: Out of the 36 subjects recruited over 7 months, 42% of patients were not able to expel the balloon. A t-test was used to compared ARM metrics, including maximum sphincter and rectal resting and squeeze pressures, duration of sustained squeeze, and residual sphincter and intrarectal pressures with bear down. In patients with a normal BET, there was a significant increase in intrarectal pressure (34 mmHg) compared to those patients who could not expel the balloon (20 mmHg, P=0.019) . No other ARM metrics, including residual sphincter pressures, were found to significantly correlate with balloon expulsion. Conclusion: Our study shows that approximately 42% of patients who present for ARM due to constipation have an abnormal BET. And an abnormal BET correlates significantly with weak intrarectal pressures with bear down, and vice versa, and not with a dyssynergic pattern on ARM. Possibly, the inability to expel the balloon is less so associated with inability to relax intra-sphincter pressures during bear down but more consistent with those patients with poor intra-rectal push pressures, as seen in DD Type II and IV. Abstracts paresis, however, a subset of patients demonstrate rapid gastric emptying (RGE), which is defined as less than 30% retention at 1 hour of solid meal ingestion. The clinical significance of RGE is poorly understood. It has been classically described in dumping syndrome, and more recently, in diabetes mellitus, autonomic dysfunction and functional dyspepsia. It is hypothesized that dyspeptic symptoms may be related to increased gastric motility and reduced postprandial fundic accommodation.
Our aim was to determine the prevalence of RGE, the demographic and symptoms profile in these patients.
We conducted a retrospective, cross sectional, observational study. Adults who underwent solid gastric-emptying scintigraphy (GES) at our institution from January 2011 to September 2012 and from May 2014 to December 2015 were included. GES was performed using the standardized protocol of oral ingestion of 1 millicuries of 99m technetium sulfur colloid mixed with egg meal followed by abdominal imaging at 0, 1, 2 and 4 hours. Subjects with less than 30% retention at 1 hour were reviewed. Data was analyzed using SPSS version 20 (SPSS Inc, Chicago, IL 
Introduction:
To assess the overall improvement in symptoms in idiopathic, diabetic and post-surgical gastroparesis patients who have undergone Gastric Electrical Stimulation (GES) Therapy with or without Nissen Fundoplication (NF) and Pyroloplasty (PP) as well as Laparoscopic Sleeve Gastrectomy (LSG). Gastroparesis is a chronic functional disorder with a significant negative impact on the QOL of affected individuals. The Gastroparesis Cardinal Symptom Index (GCSI) is a symptom severity instrument with demonstrated reliability and evidence supporting construct validity and responsiveness to change in clinical status. The role of high frequency GES in clinical practice remains controversial and is not universally accepted as the standard of care. Shada et al found that laparoscopic pyloroplasty significantly improves symptoms of gastroparesis and remains an alternative to subtotal gastrectomy or GES5. Combined GES and PP has shown improved gastric emptying especially in post-surgical patients with gastroparesis. Data supporting LSG is limited. Hence no single treatment is universally accepted. Methods: A total of 39 patients who underwent GES therapy, Fundoplication, PP and LSG were retrospectively identified and included in the study. GCSI scores were obtained by telephone surveys. Descriptive statistics (frequencies and percentages, means, medians, standard deviation, min and max) were used to describe patient characteristics and GCSI scores (cumulative and sub-scores). The Wilcoxon rank sum test (for 2 groups) or the Kruskal Wallis test (for >2 groups) was used to compare the median values of outcome variables (e.g. GCSI score) between patient groups. Results: A statistically significant difference in the median Post Prandial Fullness Score between patients whose surgery involved GES compared to those whose surgery did not involve GES (P=0.047) and in the median Post Prandial Fullness Score between patients with and without comorbid depression was found.
Conclusion:
We found a statistically significant difference in the post-prandial fullness scores as well as borderline statistically significant difference in cumulative GCSI scores between patients who underwent non-GES therapy when compared to those who had GES therapy. Whether a certain subset of patients do better with a particular intervention, remains to be determined with larger studies. Ours is a multispecialty center study which aims to add to the existing literature regarding treatment options for medically refractory gastroparesis.
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Frequency of Food Hypersensitivity in Patients With Functional Gastrointestinal Disorders
Faisal Ismail, MBBS, FCPS (Med), FCPS (Gastro), FACP, FACG, Shahab Abid, MBBS, PhD, FCPS, FRCP, FACG, Safia Awan, Farheen Lubna. Aga Khan University, Karachi, Sindh, Pakistan Introduction: Food hypersensitivity (FH), irritable bowel syndrome (IBS) and functional dyspepsia (FD) have many overlapping symptoms, including abdominal discomfort, bloating and altered bowel habits, making it challenging to distinguish between the disorders. However, symptoms of FH reduce on elimination diets and relapse on a subsequent food challenge, which does not happen in IBS/FD. Up to 25% of patients with IBS may have FH. However, mostly Caucasian populations have been studied, in which the type of food consumed, and the tendency to form antibodies against common foods may be completely different compared to the south Asian population. We aimed to determine the frequency of FH in patients with IBS and FD. Methods: Adult patients diagnosed with IBS and/or FD as per the Rome ш criteria were recruited. Patients underwent serological testing against 6 main food allergens: beef, shrimp, egg white, milk, peanut, and soy-bean. Those testing positive were subjected to a food elimination diet for 4 weeks. Those showing improvement on an elimination diet were subjected to re-challenge. Changes in symptoms were documented at all stages by the well validated Global overall improvement scale (GOS) and Gastrointestinal symptom rating scale(GSRS), and a food diary was maintained.
[440_B] Symptom distribution among symptomatic patients with rapid gastric emptying [441A] Depression SS.
[441B] Demographics.
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[442A] Flow of the study.
[442B] Baseline GSRS and GOS scores of the cohort.
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Results: Two hundred patients with IBS/FD were screened. The average age of the patients was 38.6, and 55 % were male. Nineteen (38%) patients tested positive on serological testing, and were subjected to a food elimination diet. The most common food hypersensitivity was shrimp (17/89%), followed by 4 (21%) for egg-white, and 2 (10%) each for peanut and soya bean. Off these, 8 showed improvement. They were re-challenged, and were evaluated 2 weeks later, when all suffered symptom relapse. These 8 (4%) patients were diagnosed with FH. There was a statistically significant difference in both GSRS (total and component) and GOS scores at baseline between patients testing (+) and (-) on food allergen testing, mainly for diarrhea (P=0.001), abdominal pain (P=0.001) and indigestion P= Conclusion: Standardized methods were used for the diagnosis of a FH in IBS-D and FD patients. FH was present in 4 % of patients' with IBS/FD. This is compatible with literature that reports a range from 1.7-5.3%, and lower in this particular cohort than previously reported. We conclude that exclusion of a FH may be helpful in a subset of IBS/FD patients with a compatible clinical history, and intractable symptoms.
Prevalence of Irritable Bowel Syndrome Among Medical Students of Puerto Rico
Reinaldo Ramirez-Amill, MD, Esther A. Torres, MD, MACP, MACG, AGAF. School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Introduction: Irritable bowel syndrome (IBS) is characterized by chronic abdominal pain and altered bowel habits. Prevalence varies between countries, affecting 10 to 15% of the population in the United States; in Latin America, it ranges between 11 and 26% in the community. The number of studies of IBS in medical students has increased substantially around the globe and a high prevalence has been reported in this group. Data in the population of Puerto Rico (PR) is sparse. This study aimed to investigate the prevalence of IBS and associated risk factors in medical students in PR. Methods: A cross sectional study was conducted in a sample of medical students. Participants completed a self-administered, anonymous questionnaire that contained questions about general socio-demographic data, lifestyle habits, degree of subjective psychological stress and the Rome III criteria: IBS Module. Students were grouped as preclinical (first and second year) and clerkship (third and fourth year) for comparison. Results were analyzed using Chi-square (X 2 ) test and Fisher's exact test. A P value<0.05 was considered statistically significant. Results: 314 medical students (137 preclinical and 177 clerkship students) were included for analysis. Conclusion: This is the first study to describe the prevalence of IBS in medical students in PR. A higher prevalence of IBS was found as compared to that reported for medical students in other countries. Moreover, when comparing to the general population of North America and other Hispanic groups in both Central and South America, the prevalence rate of IBS in our students was relatively higher. Additional studies aimed at estimating the impact of IBS on quality of life and academic performance of the medical students are essential. Studies focusing on determining the prevalence of IBS in the general population of PR as well as identifying other associated factors are also needed.
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Responders Analysis in Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Treated With Rifaximin
Anthony J. Lembo This post hoc analysis evaluated rifaximin efficacy using modified definitions of response and recurrence. Methods: As part of a phase 3 repeat treatment trial, adults with IBS-D were treated with open-label rifaximin 550 mg 3 times daily for 2 weeks. In the original analysis, patients with ≥30% decrease from baseline in mean weekly pain score and ≥50% decrease from baseline in number of days/week with BSS type 6 or 7 stool during ≥2 of the first 4 weeks post-treatment were considered responders. Responders were followed (observation phase) for an additional 18 weeks or until recurrence (<30% decrease from baseline in mean weekly pain score or<50% decrease from baseline in number of days/week with BSS type 6 or 7 stool for ≥3 weeks of a consecutive, rolling 4-week period). Nonresponders were withdrawn from the study. The current post hoc analysis employed a modified composite definition of responders: patients with a ≥30% improvement from baseline in abdominal pain score, recorded on ≥50% of the days during the first 4 weeks post-treatment, and a BSS score ≤5 on the same days. In patients who continued into the observation phase, abdominal pain recurrence (<30% improvement from baseline in abdominal pain on ≥50% of the days in a week) and abdominal pain and stool consistency recurrence (<30% improvement from baseline in abdominal pain and BSS score >5 on ≥50% of the days in a week) for a given week or ≥2 consecutive weeks were determined. Results: 2579 patients (mean age, 46.4 y; baseline mean ± standard deviation daily abdominal pain score, 5.5 ± 1.7 and stool consistency score, 5.6 ± 0.8) were treated. A total of 1071 (41.5%) patients were classified as responders using the post hoc definition; 982 of these patients were eligible for follow-up for an additional 18 weeks (observation phase (Table) . Changes from BL were generally similar in the DR1 and IR groups. 6/12 week responder rates were higher in DR1 vs PBO patients (nominal P<0.05) for APC+1, CSBM+1, and adequate relief; and numerically higher for abdominal pain (P=0.053; Figure) . DR1 responder rates were numerically higher vs IR for APC+1, abdominal pain, and adequate relief, and similar for CSBM+1 ( Figure) . More stringent 9/12 week responder endpoints showed abdominal pain and adequate relief improvement for DR1 vs PBO (nominal P<0.05) and numerical improvement in abdominal pain vs IR (Figure) . Diarrhea, the most common AE, led to discontinuation in 3%, 6%, and 0% of DR1, IR, and PBO patients, respectively. Conclusion: Targeted LIN delivery with DR1 300μ g appears to maintain constipation relief and may enhance benefit for abdominal pain and abdominal discomfort in IBS-C patients. Further study is warranted to confirm these results. Methods: After selecting patients with age over 18 years from the 2014 Nationwide Inpatient Survey (NIS) and using the ICD-9 codes to identify individuals with CUD, IBS and the established risk factors for IBS, we estimated the crude and adjusted odds ratio (COR and AOR) of having a diagnosis of IBS with CUD. We then assessed for the interactions of CUD with other risk factors (SAS 9.4) and confirmed our findings in two ways: conducting a similar analysis of a prior (2012) NIS data; using a greedy algorithm to design a propensity-scored case-control (1:10) analysis.
[445] Change from Baseline in Abdominal and Bowel Symptoms
Abdominal pain [445] .
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The American Journal of GASTROENTEROLOGY Results: Six patients with active IBD (disease location: rectal disease-3, ileal disease-2 and left colon-1) were included and data regarding demographics, disease duration, disease characteristics and data regarding clinical, endoscopic and histological disease activity were obtained ( Table 1) . Results of ARM are depicted in Table 2 . The mean and maximal resting rectal and anal sphincter pressures were higher in IBD patients than non-IBD group and comparable to healthy volunteers. The maximal squeeze anal and rectal pressures were almost two times higher than the non-IBD group, though not statistically significant. The sensory level for first sensation, urge to defecate, discomfort and maximum rectal compliance were lower in those with active IBD.
Conclusion:
Patients with active IBD with FI have a different anorectal pressure profile compared to non IBD patients who suffer from FI. The major difference in anorectal pressure profile appears to be in the anal squeeze pressures, possibly representing a compensatory mechanism; sensory threshold on the other hand were low. Based on these results we suggest that management of FI in IBD should focus on treatment of inflammatory and non-inflammatory diarrhea burden before considering biofeedback and pelvic floor retraining. More studies are needed to assess the anorectal function in patient with IBD. Use of concomitant probiotics 2.3%(4) 5% (1) complications from treatment 0.59 (1) 20 (4) IBS-Inflammatory Bowel Syndrome; C-Constipation; D -Diarrhea.
[448] Duration in months for complete remission of IBS.
S239
Abstracts
as an important mechanism of IBS. Alterations in the stability and composition of gut microbiome is seen in patients with IBS.Manipulation of microbiota have shown to improve the symptoms in IBS patients [1] . We have hypothesized that daily consumption of homemade yogurt containing lactobacilli can supplant the GI microflora, and can be used for treating irritable bowel syndrome. Methods: We prospectively included consecutive patients diagnosed with IBS, who consented for participation from January 2014 to May 2017 at two centers in Eastern Kentucky. IBS was categorized based on patient's predominant bowel habit. Handouts for homemade yogurt preparation from milk were provided, and patients were advised to take 2-3 cups daily. Patients were followed up every 2 months for 6 months. Daily consumption of yogurt and symptom improvement were recorded on a self reported chart. Complete remission was defined as relief of pre existing IBS symptoms and 1-2 normal bowel movements per day.
Results: 189 patients with IBS were included in the study.All patients tolerated yogurt well. 5 patients discontinued therapy prior to 6 months(3 due to inconvenience; 2 due to unpleasant taste). Study population included predominantly females (63%) and the mean age of the cohort was 49yrs. 93% (169) of the cohort acheived complete remission with no side effects ( Table 1 ). The average consumption was 2 cups per day in both groups. 46% of patients had previous coloscopy. Concomitant probiotics usage was 2.6% and not statistically significant in both cohorts. On logistic regression analysis, duration of yogurt consumption for at least 6 months was associated with complete remission (95% CI: 5.69 -6.51, P<0.00001) (Figure 1 Introduction: Chronic abdominal pain (CAP) can be disabling for patients and incur major social and economic burden given the lack of effective therapies. The role of the central nervous system and the "brain-gut axis" is central to the impaired neural processing of visceral stimuli in patients with CAP. Underlying psychiatric conditions also contribute to stress and negative emotions which magnify frequency and severity of symptoms which may contribute to increased patient care encounters. In this study, we reviewed a 10-year history of outpatient experience with this population to better understand health resource utilization associated with the management of the functional GI disorder (FGID) population. Methods: Administrative billing data from a large tertiary care medical center (1/1/07-12/31/16) was used to identify cases of functional GI disorders (FGID), including chronic abdominal pain (CAP) with and without underlying psychiatric co-morbidity. Descriptive analysis of demographic and clinical characteristics, and longitudinal practice trends were examined. Cases were propensity-matched in a 1:1 fashion to controls. Generalized estimating equations were created to predict health resource utilization of interest (endoscopy, radiology) and Poisson regression used to quantify GI return visits and Emergency Department (ED) visits. Psychiatric co-morbidity was treated as an effect modifier to better evaluate the impact of this underlying condition on health care utilization. Results: We identified 31,324 patients with FGID (cases), of which CAP was the primary diagnosis in 13,271; cases were matched to 48,434 controls. The median age was 59 years (49-69), 55% were female,
[449] .
93% white, 64.9% had commercial insurance and 37% had a Charlson-Deyo score ≥ 1. Psychiatric comorbidity was greater among cases vs. controls (11.7% vs. 8.0%; P<0.001). Overall healthcare utilization was higher in cases vs. controls with strongest association among those with psychiatric co-morbidity ( Figure 1 
Introduction:
The sense of incomplete evacuation is a feature of a defecatory disorder-however the mechanism of evacuation is not well understood. The aim of this study was to use simultaneous barium defecography and high resolution anorectal manometry (HRAM) to elucidate the mechanism of defecation in patients and controls Methods: Simultaneous seated HRAM and defecography (using180ml barium paste) were performed in 26 constipated women and 22 asymptomatic controls. Anal diameter and rectal pressures during evacuation and percentage of barium emptied, and the rectoanal pressure gradient during evacuation were calculated. Values less than 25th percentile for controls was considered abnormal. Results: Healthy women evacuated 80% of barium paste (median, IQ range-18-90%) while patients evacuated 21% (0-70%). Five controls and 12 patients evacuated < 18% of barium (25th percentile for controls). They were classified as "poor-evacuators" or PE); of these 9 had an abnormal balloon expulsion test (>60 seconds). The rest were classified as "adequate evacuators" (AE). Rectal and anal pressures increased initially during evacuation in all women. Thereafter, anal pressures declined, but the rectoanal pressure gradient exceeded 0 mm Hg only in AEs, enabling evacuation in this group. Rectal pressure at the onset of evacuation (median 87 vs 47mmHg, p=0.1) and anal diameter during evacuation (13 vs 0mm, p=0.002) was greater in AEs than PEs. Among AEs, a moving average of recto-anal pressure gradients (median = 4.2 mmHg) was positive (>0 mm Hg) for a median duration of 5s, which is 60% of the median duration of evacuation (8.5s). Among constipated PEs, disturbances were inadequate rectal pressure (4 patients) or impaired anal relaxation (8 patients).
In a multivariate linear regression model, the rectoanal gradient, average anal canal diameter, and duration of anal relaxation during evacuation explained 40% of the variation in percent of barium emptied (p=0.0001).
Conclusion:
Adequate evacuation of barium (≥18%) is characterized by an initial simultaneous increase in rectal and anal pressure followed by anal relaxation. Conversely, either an inadequate increase in rectal pressure or in anal diameter during evacuation leads to incomplete evacuation. Not all women who have poor evacuation are symptomatic. The simultaneous increase in rectal and anal pressures during evacuation may be mediated by a reflex induced by increased abdominal pressure. Simultaneous defecography with HRAM may be useful in the clinical evaluation of chronic constipation. Introduction: Rumination syndrome (RS) is an under-recognized disorder characterized by regurgitation of swallowed food and liquids within minutes after ingestion. Patients experience frustration due to the lack of awareness of this entity. We report a single-center series of RS emphasizing the spectrum of presentation as well as treatment options and outcomes. Methods: Patients with RS were identified from 2015 until 2017. All were referred to a tertiary care center for unexplained regurgitation and/or vomiting as well upper abdominal pain. Data was collected regarding their diagnosis of RS based on medical records, clinic visits, and also phone interviews. All patients received breathing and relaxation techniques as well as pharmacotherapy with tricyclic antidepressants (TCA), antiemetics, and PPIs. Nocturnal nutritional support via a feeding jejunostomy (J-tube) was required to maintain stability in a subset of patients with severe weight loss, dehydration, and frequent hospitalizations. Results: 12 patients, age range 17 to 82 years (mean 40), 50% female, met criteria for RS. Time to diagnosis ranged from 4 months to 4 years after symptom onset, however, one patient had symptoms for 17 years prior to diagnosis. The working diagnoses for the patients' regurgitation/vomiting were achalasia, gastroparesis, and GERD, while the abdominal pain component was attributed to gastritis, peptic ulcers, irritable bowel syndrome, and cholelithiasis. Some patients were able to attribute their improvement to a specific treatment modality. One patient was able to tolerate symptoms without treatment; two patients had the greatest improvement with breathing/relaxation techniques alone; two reported the most help by complementing these techniques with medications--amitriptyline in doses ranging from 20 mg to 125 mg, and two found that medications were most helpful. Six patients had J-tubes placed for an average of 4 months reported that this allowed them to focus on the breathing techniques because of increased energy. Pain management focused on reducing abdominal wall pain by breathing treatment while tapering and avoiding narcotics. Conclusion: Our data highlights the following aspects of RS: 1.Diagnosis is delayed due to confusion with many other entities. 2.Patient presentation varies from well-tolerated regurgitation to severe weight loss and dehydration. 3.Treatment requires mastering of breathing techniques that can take some weeks for full efficacy, combined with TCA therapy, and/or nutrition support.
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Evaluation of Rate of Depression and Anxiety in Patients Presenting for Hydrogen Breath Testing
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Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis
Timothy Yen, MD, Frank Chen, MD, Ronald Witteles, MD, Michaela Liedtke, MD, Linda Anh Nguyen, MD. Stanford University School of Medicine, Stanford, CA
Introduction: Gastrointestinal (GI) symptoms in systemic amyloidosis patients are poorly characterized. This purpose of this study is to define the epidemiology and clinical implications of such symptoms in the context of endoscopic investigation.
Methods: This was a retrospective single center cohort study of 583 amyloid patients seen at a tertiary referral center from June 2008 to January 2017. Of 96 symptomatic patients, 82 received endoscopic biopsies (either esophagogastroduodenoscopy or colonoscopy), subsequently grouped into those with histologic evidence of GI amyloid (biopsy proven) versus those without (biopsy absent) ( Figure 1 ). Analysis was done with Fisher exact test or Mann-Whitney U test with p < 0.05 denoting significance. Results: 16.8% of patients had GI symptoms. 84.4% of these patients had light-chain (AL) amyloidosis, 12.5% had transthyretin (TTR) amyloidosis, and 3.1% had other types of amyloidosis. Of the 82 symptomatic patients who received endoscopy, only 37 (45%) had biopsy proven GI amyloid. The sites of highest diagnostic yield were the stomach (30.0%), duodenum (38.6%), ileum (36.4%) and colon (26.7%). The most common symptom was abdominal pain/nausea/vomiting (50.0%) followed by weight loss (40.2%) and diarrhea (26.8%). 23.2% received functional GI diagnostics, 73.2% got acid suppression, 28.0% got neuropathic or motility agents, and 7.3% got non-pharmacologic therapies (Table 1) . Biopsy proven patients more often had cardiac amyloid (p < 0.005), and more often received hematologic therapy or transplant (p=0.01). Biopsy absent patients had slightly more frequent neurologic involvement (p=0.17-0.31) ( Table 2) . Biopsy results had no significant correlation with other organ involvement, burden of organ involvement, GI symptoms, or motility-specific management (Table 1 
Introduction:
The purpose of this study was to determine if online, case-based continuing medical education (CME) could improve knowledge and competence of gastroenterologists and primary care physicians (PCPs) in assessing and managing patients who have irritable bowel syndrome with diarrhea (IBS-D).
Methods:
• Physicians participated in a text-based, online CME activity composed of 2 patient cases with interactive questions on assessment and therapeutic selection for IBS-D.
• Evidence-based educational feedback was provided following each answer.
• Effects of CME were assessed using a repeated-question pairs pre-to post-assessment study design where individual participants served as his/her own control.
• The assessment included 3 multiple-choice knowledge/competence questions and 1 self-efficacy question that rated confidence in managing IBS-D on a 5-point Likert Scale.
• For all questions combined, McNemar's chi-square test assessed the differences from pre-to postassessment.
• P values measured significance; P values <.05 were considered statistically significant.
• Effect size was calculated using Cramer's V by determining the change in proportion of participants who answered questions correctly from pre-to post-assessment.
• Survey data were collected from March 25, 2017, to April 26, 2017 Results:
º Data set included 338 gastroenterologists and 788 PCPs who completed all assessment questions during the study period. º Gastroenterologists:
Knowledge/competence improved (P<.001; V=0.553; large educational effect) following participation in the CME activity • While 4% answered all 3 questions correctly on pre-assessment, 79% answered them all correctly on post-assessment, with the largest increases on incorporating appropriate scales to diagnose IBS-D • 23% reported being more confident in their ability to manage IBS-D following the CME activity.
º PCP:
Knowledge/competence improved (P <.001; V=0.646; large educational effect) following participation in the CME activity º While 2% answered all 3 questions correctly on pre-assessment, 70% answered them all correctly on post-assessment, with the largest increases on incorporating appropriate scales to diagnose IBS-D º 41% reported being more confident in their ability to diagnose PBC following the CME activity. Conclusion: Online CME in a clinically relevant case-based format can improve knowledge, competence, and confidence in IBS-D management, and better equip physicians to translate these improvements to benefit real patients. 
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Constipation Symptoms Differ Between Individuals With Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation
Introduction:
We characterized constipation symptoms among individuals with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Methods: Adults (>18 years of age) were identified from a nationwide sample of over 70,000 US adults meeting modified Rome III criteria for IBS-C or CIC. Dimensions of the constipation experience were assessed using the validated GI-PROMIS® questionnaire administered by the novel ehealth app MyGIHealth. Question items were developed using systematic literature review followed by open-ended questions in patient focus groups. Question items were mapped onto a matrix according to pre-defined dimensions within the conceptual framework of constipation symptoms. Content validity, patient understanding, and reliability were established in semistructured interviews and a subsequent multi-center survey. Odds ratios (OR) with 95% confidence intervals (CI) were calculated using logistic regression to evaluate responses in IBS-C relative toCIC which were previously mapped onto five-point response scales. Differences in GI-PROMIS scores (range=0-100, mean=50, standard deviation=10) were assessed using one-way ANOVA. Results: 970 individuals met eligibility criteria (275 with IBS-C; 734 with CIC). Demographics were similar except for education, marital status, employment status, and income. GI-PROMIS scores, as a composite measure of frequency and severity, were higher in IBS-C (score=75) compared to CIC (score=68) (p=0.01). Among first-order individual question items within the constipation symptom domain, there were differences in constipation symptoms reported by IBS-C and CIC. IBS-C patients had more hard or lumpy stools, rectal pain frequency, and need for digitation though overall bothersomeness was similar between the groups (Table) . No items in the instrument favored more severe or frequent symptoms in the CIC cohort.
[453] .
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The American Journal of GASTROENTEROLOGY VOLUME 112 | SUPPLEMENT 1 | OCTOBER 2017 www.nature.com/ajg Abstracts Conclusion: GI-PROMIS scores are higher in IBS-C compared to CIC individuals. Given the striking overlap between symptoms in patients with IBS-C and CIC, it is reasonable to hypothesize that IBS-C and CIC reside upon a spectrum of disease severity with CIC patients representing the less severely affected end of the spectrum and IBS-C representing the more severely affected end of the spectrum. 
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Understanding How Low FODMAP Diet Fits into the IBS Treatment Paradigm: A CostEffectiveness Analysis of Low FODMAP Diet versus Guideline-Recommended Prescription Therapy
Introduction:
Payer coverage decisions and out-of-pocket cost exert profound effects on access to effective treatment for irritable bowel syndrome with diarrhea (IBS-D). We performed a cost-effectiveness analysis to assess the tradeoffs associated with treating IBS-D with dietician-directed low FODMAP diet modification or prescription therapy (guideline-recommended with at least grade B supporting evidence or more recently approved for treating IBS-D). Methods: We constructed a decision analytic model evaluating potential first-line use of relevant treatment strategies. This model accounted for direct and indirect costs of therapy (Medicaid NADAC database and Healthcare Blue Book) and work-productivity loss (published literature and US Bureau of Labor) with a 3% per annum discount rate. Responder and discontinuation rates were derived from clinical trial data, and validated health utility values were assigned to terminal health states. Base-case analysis was performed to determine incremental cost-effectiveness ratios (ICER) relative to competing strategies, in reference to contemporary willingness-to-pay (WTP) thresholds per quality-adjusted life year (QALY) gained. Analysis was performed with a 1-year time horizon from payer and patient perspectives. Appropriate sensitivity analyses were conducted. Results: Low FODMAP diet was the most effective overall treatment strategy. From a payer perspective (Figure 1 ), low FODMAP diet was less costly than rifaximin and eluxadoline (hence more cost-effective) and could be cost-effective compared to TCA dependent on the assumed WTP threshold. From a patient perspective (Figure 2 ), low FODMAP diet was more expensive than all prescription IBS therapies, however low FODMAP diet could still be cost-effective compared to rifaximin, eluxadoline, or TCA depending on the assumed WTP threshold. In sensitivity analysis from a patient perspective, low FODMAP diet was the preferred therapy at lower food costs and lower work-productivity losses due to poorly managed IBS (i.e. more mild disease) (Figure 3) . Conclusion: Low FODMAP diet is effective for managing IBS-D and generally cost-effective from a payer perspective. However, cost-effectiveness from a patient perspective depends on case-by-case assumptions regarding cost of food and impact of poorly managed IBS on work-productivity. Clinicians should consider cost-effectiveness when recommending IBS therapy.
[456] Responses to constipation question items characterizing the constipation experience in IBS-C and CIC [457A] Cost-effectiveness of low FODMAP diet vs. prescription therapy for IBS-D from a payer perspective. The incremental cost-effectiveness ratio for implementing low FODMAP diet is $58,039 per QALY-gained in relation to a TCA-based treatment strategy.
[457B] Cost-effectiveness of low FODMAP diet vs. prescription therapy for IBS-D from a patient perspective. Incremental cost-effectiveness ratios ($/QALY-gained) are presented for the low FODMAP diet strategy in relation to rifaximin, TCA, and eluxadoline treatment strategies.
[457C] Sensitivity analysis to determine the preferred IBS-D treatment strategy from a patient perspective, based on cost of low FODMAP food (as a percentage of usual food costs) and work-productivity losses due to poorly managed IBS. Lower food costs (as a % change compared to usual food costs) and fewer productive work-days lost to IBS (as a surrogate for more mild IBS) could increase cost-effectiveness and preferability of low FODMAP diet modification vs. prescription therapy. Results are presented from a patient perspective at a WTP level of $100,000/QALY gained.
Introduction: Constipation is a major public health issue worldwide and is associated with significant health care financial burden and reduced quality of life. About half of the patients are dissatisfied with the treatment prescribed. There is a lack of data on patients understanding of constipation; we therefore aimed to understand the nature of patient's defecatory disorders by using ROME III criteria. Methods: A cross-sectional study was carried out in outpatient gastroenterology clinics of two major hospitals of Karachi-Pakistan; one public and other was private tertiary care hospital. [462A] .
[462B] .
[461_A] Characteristics of Gastric Emptying at 1, 2, and 4 hours and Center for Epidemiology Studies-Depression scale (CESD), and the modified bowel symptom severity scale (BSS). These measurements were collected at pre, post, and 3 months follow-up of the intervention. Veterans were asked if their symptoms worsened, showed no change, or improved at post-intervention and 3 months follow up. The BSS questionnaire was completed by 15 Veterans who reported that GI symptoms were one of the higher priorities of their GW Illness symptoms. The BSS comprises: (i) severity of abdominal pain (0-100, none to severe), (ii) severity of bloating (1-100, none to severe), (iii) stool frequency, (iv) stool consistency (Bristol stool scale, 1-7, very hard to watery), (v) severity of diarrhea (0-100), (vi) severity of constipation (0-100), (vii) how satisfied are you with bowel habits (0-100), and (viii) how much is IBS affecting or interfering with your life (0-100).
Results: A total of 160 GW Veterans with sleep disturbances were screened and n=73 (men=67 (92%) were enrolled in the study, with age range of 39-69 years (median=50 years). The sleep scores assessed by MOS-SS in these Veterans ranged from 33.9-97.8 (mean±SD 64.2±15.0). The GI symptoms were selfreported by n=52/73 (71.2%) participants, Further breakdown of symptoms included: IBS=17 (23.3%), diarrhea 18 (24.7%), constipation 27 (37%), excessive gas 23 (31.5%), abdominal pain/cramps 27 (37%), reflux disorder or stomach ulcer n=33 (45.2%), Crohn's and colitis= 2 (2.7%), others 15 (20.5%). There was no difference in the severity of sleep disturbance scores between those with and without GI symptoms (Table 1) . Similarly, there were no differences in sleep scores between those with and without IBS (mean scores (69.5, vs. 62.2, P=0.09), From the 52 Veterans with GI symptoms, 45 were randomized to treatment (MBB n=24 and SED n=21). Overall treatment (MBB and SED) resulted in improvement in sleep, PTSD, depression and QOL. There was no difference in improvement between two treatments among these Veterans with GI symptoms, as both treatment groups showed improvements. There was no significant improvement in GI symptoms as assessed by BSS, following the interventions (post, and 3 months follow up (Table 2) .
Conclusion:
The quality of sleep was basically comparable across the two groups of Veterans with and without GI symptoms. MBB and SED improved sleep, PTSD, depression, and overall QOL, but did not improve GI symptoms in GW Veterans. The association and effect of sleep disturbances on GI symptoms needs further investigation. 
Dietary Fructan Intolerance Another Jigsaw in Irritable Bowel Syndrome (IBS) Puzzle
Introduction:
Fructan are polymerized fructo-oligosaccharides that are present in wheat, onion, garlic, artichoke and other common foods, with an estimated daily intake of 1-20 g in USA.
Fructans are believed to be completely malabsorbed but we found that 33% of healthy humans do not show malabsorption. Fructan maldigestion may cause symptoms and intolerance in patients with IBS. We aimed was done and all patients complaining of constipation and consenting to participate in the study were included. Patients with alarm features (GI bleeding and weight loss) were excluded. Face to face interviews were conducted by trained doctors using a structured Rome III based pre-tested questionnaire and Bristol Stool Scale scoring system. Results: A total of 396 study participants were enrolled with mean (SD) age 38.8(14.7) years. Out of these 210(53%) participants were men. Irritable bowel syndrome-constipation (IBS-C) was present in 209(52.7%) and remaining 186(46.9%) had fulfilled the criteria of functional constipation (FC). Of all the participants, 214(54.0%) reported to have slow transit constipation based upon Bristol Stool Scale (Figure 1 ). Some accompanying symptoms reported by patients include sensation of incomplete evacuation (69.2%), feeling of abdominal distension (63.9%) and bloating (74.2%).
Frequency of other symptoms reported by study participants and gender differences are given in Table 1 . In our study FC was found to be more common amongst men (66.1% vs. 33.9%) whereas IBS-C was more common amongst women (57.9% vs. 42.1%, P < 0.001). A higher proportion of women reported more severe form of constipation as compared to men (83.3%, n=150 vs. 66%, n=138 P < 0.001). However, a higher percentage of men reported using medications to treat their symptoms (71.2%, n=151 vs. 57.1%, n=105, P=0.003). Various treatment modalities used by study participants are shown in Figure 2 . Conclusion: Almost half of the patients were not suffering from slow transit constipation. A large number of patients had diverse accompanying defecatory symptoms. Proper understanding of patient's symptoms is essential for optimizing individual patient management. Introduction: Coeliac disease (CD) is estimated to affect up to 1 in 100 Australians. Although CD has a wide range of clinical manifestations, patients frequently present with gastrointestinal (GI) symptoms which overlap with functional GI disorders such as irritable bowel syndrome (IBS) or functional dyspepsia (FD).Patients with CD have been shown to experience persistent GI symptoms despite long term treatment with a gluten free diet.
Methods:
The aim of this study was to define GI symptoms reported in an Australian cohort with a doctor diagnosis of CD and compare with those not reporting CD. A total of 3825 people (mean age 58.4 years, age range 18-100 years and 47.5% males) randomly selected from the Australian population returned a mail survey (Digestive Health & Wellbeing Survey, response rate=45%) which contained questions on whether the participant had ever been told by a physician that they had CD, and GI symptom questions to establish whether they had co-existent functional GI disorders. Adherence to a gluten free diet was not assessed. Prevalence of CD, FD and IBS are reported with 95% exact confidence intervals. The difference between symptoms in CD compared with the unaffected population was tested for significance using a Pearson chi-square test.
Results:
The prevalence of doctor diagnosed CD was 1.17% in this cohort. Subjects with CD reported significantly higher levels of GI symptoms than unaffected individuals, including abdominal pain associated with abnormal bowel habit, diarrhoea, bloating, distention, epigastric burning and early satiety (see Table 1 ). There was no significant difference observed in symptoms of post-prandial fullness, nausea, constipation, abnormal stool consistency, or straining with defecation. The prevalence of FD as defined by Rome III criteria in the CD cohort was 37.5% (95% CI 22.7-54.2) compared to 13.9% (95% CI 12.8-15.1) in the non-affected population (OR 3.7, 95% CI 1.9-7.1, p < 0.001). There was no significant difference in the prevalence of IBS in the affected compared with the non-affected cohort (30.8% versus 22.2%, p=0.2).
[463] Gastrointestinal symptoms reported in patients with and without coeliac disease (CD). Items reported as greater than one day per week (*) or greater than or equal to "often" (**) 
Abstracts
(1) To assess the feasibility of fructan breath test (FrBT), (2) To investigate whether dietary fructan intolerance causes IBS. Methods: Patients with IBS (Rome III), negative GI evaluations (endoscopy and CT), and negative glucose breath tests were evaluated. After an overnight fast, subjects ingested 10 g of fructan dissolved in 100 cc water. H 2 and CH 4 samples were collected at baseline and every 30 minutes for 3 hours. A change ≥ 20 ppm over baseline H 2 or ≥ 15 ppm over baseline CH 4 values were considered positive. AUCs and time to peak gas production were calculated. Symptoms were assessed at baseline and during the FrBT. IBS symptom reproduction, abdominal pain, cramping, bloating, fullness, nausea, indigestion, diarrhea, gas, distention was recorded using a likert scale of 0-3. Symptom scores were compared between negative test group and intolerance. Results: 102 patients (f/m=73/29, mean age 50 years) were evaluated. Positive FrBT were found in 65 (64%), and 52(51%) had reproduction of their IBS symptoms. Negative FrBT were found in 37 (36%), and 17(16%) had reproduction of their IBS symptoms. The mean peak rise in H 2 was 69ppm, and mean time to reach peak of 2.1 hours, and the mean H 2 AUC was 92ppm-hours. In patients with positive test, the peak rise in CH 4 was 25ppm, the time to reach peak was 2.1 hours, and CH 4 AUC was 46.3ppm-hours. Significantly greater number of patients with positive FrBT showed IBS symptom reproduction during test (52 vs 17, P < 0.05) than those with negative test (mean 26.8 versus 31.8, P=0.49). Overall symptom score was similar between groups (mean 26.8 vs 31.8, P=0.49).
Conclusion:
In a selected group of patients with IBS, approximately 64% had fructan malabsorption and 51% had fructan intolerance. The dictum that dietary fructan are always malabsorbed in humans seems incorrect. Symptoms appear to be poor predictors of a positive or negative test. FrBT is safe, practical, and useful test. It could help to identify a subgroup of IBS patients that may benefit from a targeted trial of low fructan diet, rather than FODMAP restricted diet.
[ 
Introduction:
The role of the low FODMAP (fermentable oligo-, di-, mono-saccharides and polyols) diet has gained increasing acceptance for the treatment of irritable bowel syndrome (IBS) but potential safety concerns have been raised regarding nutritional adequacy. Changes in micronutrient intake with a low FODMAP diet have not been previously investigated. Daily micronutrient intake after 4 weeks of a low FODMAP diet or a modified NICE (mNICE) diet was compared to baseline.
Methods:
A post-hoc analysis of a single-center, randomized-controlled trial of adult patients with IBSDiarrhea (IBS-D) was utilized which compared the efficacy of a low FODMAP and the mNICE diets on IBS symptoms over a 4-week period. The Nutrition Data System for Research (NDSR) computer program was used to analyze 3-day food diaries at baseline and at 4 weeks. Results: Data from 78 patients who completed the study were included. 41 patients were randomized to the low FODMAP diet and 37 patients were randomized to the mNICE diet. The average BMI in the low FODMAP group was 27.7 ± 6.5 compared to an average BMI of 31.4 ± 7.9 in the mNICE group (p=0.003). Both diets resulted in fewer daily kilocalories and number of daily meals consumed (Table 1) . Among the patients on the low FODMAP diet, a statistically significant decrease from baseline in the daily intake retinol, thiamin, riboflavin, calcium, and trans-fatty acids was observed. There was a statistically significant increase from baseline in the intake of vitamin B6. In the mNICE group, there was a statistically significant decrease in the daily intake of polyunsaturated fatty acids only. The remaining micronutrient differences compared to baseline were not statistically significant. Conclusion: During a 4-week dietary intervention, the average daily intake of most micronutrients remained stable and within recommended dietary allowances. A low FODMAP diet was associated with a significantly lower daily intake of retinol, thiamin, riboflavin, calcium, trans-fatty acids, while the daily intake of vitamin B6 was increased. The mNICE diet was associated only with lower daily intake of polyunsaturated fatty acids. While statistically significant, the clinical significance of these findings are unclear and suggest that for a short-term elimination diet, the low FODMAP diet is not associated with major micronutrient inadequacies. These findings reinforce the importance of diversifying a patient's diet through reintroduction of foods containing FODMAPs.
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Clinical p=0.27 ) and that of bloating was 0.40 p=0.27 ). Both of the later did not reach statistical significance. Although diarrhea was more commonly found in patients with SID, given our small sample size, the above findings are not sufficient to conclude that diarrhea is more commonly seen in patients with SID. Also an interesting was the finding of concomitant lactase deficiency (n=18) in 100% of patients with sucrase enzyme deficiency (n=10).
Conclusion: Sucrase maldigestion, should be considered in patients with chronic diarrhea but perhaps not necessarily in those with IBS-D/M as our findings surprisingly showed abdominal pain to be less frequently seen in those with SID. Bloating was also less frequent in those with SID although this was not statistically significant. Future studies should be expanded on the clinical parameters in patients with SID and then determine if this subset of patients will respond to dietary modification and/or digestive enzyme (Sucraid®) replacement. 
Introduction:
There is emerging interest in interdisciplinary care for irritable bowel syndrome (IBS), given patients low response to conventional medical treatment. Current clinical guidelines recommend behavioral interventions for IBS; however, patients are not routinely referred to behavioral medicine. A referral toolkit for gastroenterology (GI) providers may enhance referral rates and bridge this gap. Aim: To better understand provider perceptions of behavioral medicine to inform the development of referral procedures. Methods: As part of an ongoing formative evaluation, we conducted in-depth, semi structured interviews with GI and behavioral medicine providers (n=6) in an academic medical center (AMC) and a Veterans Affairs medical center (VAMC). We assessed providers 'attitudes toward behavioral medicine, communication strategies, referral practices, and barriers and facilitators to treatment attendance. We used rapid qualitative analysis to identify preliminary themes, which will inform development of the referral toolkit. We performed a prospective, double-blind, placebo-controlled, cross-over trial of 10 patients with both FD and IEM. Patients were randomized to one of two groups for a period of six total weeks. Group A patients were treated with buspirone for two weeks followed by a two-week washout period and subsequently treated with placebo. Patients in Group B were treated with placebo for the first two weeks and buspirone the last two weeks. Outcomes measured at baseline, end of week 2, and week 6 include the Mayo Dysphagia Questionnaire-14 (MDQ-14), the GERD-HRQL, and HREM. A sample size of 10 patients was found to have 80% power to detect a difference of 25% in the number of failed or weak swallows.
Results:
The mean age of our 10 patients was 53 +/-9 years and 70% were female. While 70% of the patients treated with placebo had IEM, only 50% of those treated with buspirone had IEM. However, this difference was not statistically significant. Furthermore, when comparing those treated with placebo with those treated with buspirone, there was no statistically significant difference in resting lower esophageal sphincter pressure, median integrated residual pressure, mean DCI, or percentage of swallows weak, failed, or normal (Table 1 ). There was also no statistically significant difference in any of the questions in the MDQ-14 or the GERD-HRQL (Table and Figure 1 ). Of note, patients had a statistically significant decrease in the total GERD-HRQL total score when treated with placebo compared to baseline levels. Conclusion: Despite previous data showing improved motility in healthy volunteers, our study shows no difference in terms of HREM parameters or symptom scores in FD and IEM patients treated with buspirone compared to placebo. Further research is necessary to identify novel agents. Introduction: Dyssynergic Defecation (DD) is the most common cause of constipation in tertiary referral centers and is predominantly found in women. Previous studies have established a positive association between age and DD. While lack of estrogen has been implicated in pelvic floor weakness, it has rarely been studied in relation to DD. In addition, no study has used 3D High Resolution Anorectal Manometry (3D-HRARM) to decipher if a relationship exists between women with a confirmed diagnosis of PFD and menopausal status. Methods: A retrospective review of all (3D-HRARM) was performed at the Drexel University College of Medicine Gastroenterology Motility Center between January 2015 and August 2016. Background data on female patients was collected as well as risk factors for DD including: surgical history, obstetric history, menopausal status, hormone replacement, birth control, history of episiotomies, and history of abuse. Results: Of the 3D-HRARMs completed, 88%(157/179) were female and 91%(143/157) of the females had an abnormal 3D-HRAM. The subset of abnormal 3D-HRAMs with pelvic floor dysfunction (PFD) was 62% (97/157). These women were further subdivided into Type -1(35%;34/97), -2(9%;9/97), -3(31%;30/97), and -4(25%;24/97). Fifty percent (55/109) were postmenopausal. Systemic or local hormone use in postmenopausal women was clearly documented in 20%(11/55) and 7%(4/55) respectively. When comparing women with PFD and without PFD, there was a significant difference noted in age (49 vs 44, p Conclusion: This is the first study to specifically evaluate the relationship between women with a diagnosis of PFD by 3D-HRARM and menopausal status. We raise the possibility that menopausal status in addition to traditionally taught risk factors, is integrally involved in the development of PFD. The lack of correlation between PFD and hormonal replacement in postmenopausal women may be secondary to our small numbers; however, we strongly suggest that post-menopausal women with symptoms of DD be referred for anorectal physiologic studies.
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The *Adverse drug reactions were defined as treatment-emergent adverse events that were considered by the Investigator to be definitely, probably, or possibly related to study drug.
[479] Change from Baseline* to Each Week (LS Mean ± SE) in Assessed Endpoints. widely available and reimbursement is problematic. We tested the efficacy of home device assisted BT against standard office BT. Methods: Patients with FI (at least 1 episode /week) were randomized to office BT or home BT using a novel biofeedback device (InToneMV, InControl Medical, WI, USA). Home device consists of a probe with balloon, a pump for balloon inflation, a hand held monitor with voice guided therapy, and both mechanical and electrical stimulation of anal sphincters. Home BT patients were asked to use home device twice daily for 20 minute session. Office BT patients practiced Kegel exercise twice daily at home and had 6, one hour, weekly office BT consisting of anal strengthening, endurance training and coordination training for 6 weeks. All participants kept daily stool diaries. Bowel symptoms, fecal incontinence severity index (FISI), fecal incontinence and constipation assessment (FICA), subject's global assessment (SGA) and physiological changes (anorectal manometry) were assessed at baseline Abstracts from sensitized rats were hyperexcitable versus controls, with significantly increased resting membrane potential, reduced rheobase, increased action potential firing and increased current density in response to TRPV1 agonist capsaicin. Colon-specific DRG hyperexcitability was significantly reduced in tenapanortreated rats (Table) . Conclusion: Oral tenapanor reduced visceral hypersensitivity in an established model of IBS-like colonic hypersensitivity in rats; this was accompanied by normalization of colonic sensory neuronal excitability and TRPV1 currents. Together, these data describe the first mechanistic link between tenapanor and specific nociceptive pathways such as TRPV1 signaling, previously suggested by both rodent and human studies to play an important role in the pathogenesis of colonic hypersensitivity in IBS. Methods: This is a retrospective, cohort study from a database subset analysis. Patients who scored >7 on either the HADS anxiety or depression measure, and had a psychiatrist determining that psychological intervention is indicated, were recruited. HADS and IBS-QOL questionnaires were administered at recruitment and 3 months after psychological treatment. Patients who defaulted the planned psychologist sessions were regarded as controls. The effects were assessed by comparing HADS and IBS-QOL. Ethics committee approval was obtained.
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Results: 39 patients were included in this study. They had a mean HADS-Anxiety score of 10.85 (SD3.083), HADS-Depression score of 5.92 (SD4.016), and average total IBS-QOL score 82.787 (SD29.966). 12 did not attend their psychologist sessions, 16 underwent supportive psychological intervention and 11 underwent cognitive behavioual therapy. For those who did not attend, those who had supportive psychological support and those who underwent CBT, the mean difference in HADS-Anxiety score was 5(SD4.2), 3(SD3.8) and 6.5(SD4.1); HADS-Depression score was 1.3(SD2.7), 1.8(SD3.9), and 3.9(SD3.7), and IBS-QOL total score was 13.8(SD35.2), 7.2(SD17.3) and 20.5(SD23.5) respectively. However there was no statistical significance in the mean difference of the scores between all 3 groups. (p=0.064, 0.177 and 0.418 respectively).
Conclusion:
There is a trend towards improvement for patients who underwent CBT compared to supportive intervention and control, however further prospective studies are needed to confirm this.
486
Using , and IBS-D Global Symptom Score (GSS; 0-5 scale). Pts reported number of bowel movements (BMs) and urgency episodes daily. Adequate relief (AR) of IBS symptoms was assessed weekly. Response rates over Weeks 1-26 and change from baseline to Week 26 are displayed in radar plot format for these endpoints: primary efficacy composite response, based on simultaneous daily improvement of ≥30% in abdominal pain score vs. baseline and BSS score < 5 with ≥50% of days demonstrating a response; stool consistency response as per the primary endpoint; abdominal pain response calculated using criteria of ≥30%, ≥40%, or ≥50% improvement vs. baseline; urgency-free response calculated using criteria of ≥50% or manage comorbid conditions, identifying medications with higher emetic potential is key to evaluating a patient presenting with persistent nausea and vomiting. Restless Legs Syndrome (RLS) is a common disorder often justifying treatment with ropinirole, a dopamine agonist. Dopamine agonists are known to increase nausea and vomiting, but the prevalence of these symptoms in ropinirole users is not firmly established.
Methods:
We conducted a systematic review using PUBMED and EMBASE to identify placebo controlled trials of ropinirole treatment for adult RLS. We included only English articles published prior to December 2015. We also searched unpublished data using the Clinicaltrials.gov and GlaxoSmithKline databases. We excluded studies not reporting adverse events. We extracted the number of patients with nausea and/or vomiting symptoms from each trial. The total prevalence of nausea and vomiting was calculated for ropinirole and placebo groups. Statistical comparisons were made using Fisher's exact test (p < 0.05 taken as significant), and regression analysis was performed using a Cox proportional hazards model. Results: We identified 13 studies (7 published, 6 unpublished) to include in the meta-analysis. Nausea was more prevalent in the ropinirole-treated group compared to those taking placebo (37% vs. 9%, N=1528, p < 0.0001; HR 5.9 [4.4-8.0]). Vomiting was also more prevalent in the ropinirole-treated group compared to those taking placebo (10% vs. 2%, N=1395, p < 0.0001; HR 4.6 [3.0-7.1]). One unpublished trial reported a lower prevalence of nausea (20%) and vomiting (5%) in those taking an extended release form of ropinirole (comparison to nausea in immediate release ropinirole treatment, p=0.068). Conclusion: Greater than one third of patients treated with ropinirole experience nausea. As RLS is more widely recognized and treated, the prevalence of ropinirole-induced nausea and vomiting could grow substantially. Yet, as a relatively new medication, ropinirole use may not be recognized as a driver of chronic nausea and vomiting. Our data suggests that patients with chronic nausea and vomiting should be asked about RLS and potential ropinirole use. Stopping ropinirole in this context, or possibly switching to an extended release form, would be warranted.
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Tenapanor Introduction: Tenapanor, a minimally-systemic, small-molecule inhibitor of NHE3, acts locally in the gastrointestinal tract on intestinal epithelial cells to inhibit sodium absorption. In clinical trials in constipation-predominant IBS patients, tenapanor significantly increased abdominal pain responder rate as compared to placebo. Here we investigate the mechanism by which tenapanor reduces pain focusing on its effects both on visceral hypersensitivity and known pathways of neuronal hyperexcitability in rats. Methods: 10-day old rats were sensitized by intracolonic infusion of 0.5% acetic acid. Sensitized rats (aged 10 weeks; n=7/group) were treated orally, twice daily, with vehicle or tenapanor (0.5 mg/ kg). A laxative control group of sensitized rats received polyethylene glycol (PEG) 3350 (1000 mg/ kg). Non-sensitized controls received neonatal intracolonic saline and were treated with vehicle. Visceral motor response (VMR) to colorectal distension (CRD) was assessed by electromyography. Colon-specific dorsal root ganglia (DRG) sensory neurons were labeled in vivo with DiI injection into the colon, and their excitability in response to in vivo tenapanor treatment was assessed by single cell patch clamping. Results: Tenapanor abolished visceral hypersensitivity resulting in similar VMR responses to CRD to non-sensitized controls (Figure) . By contrast PEG 3350 had no effect. Colon-specific DiI(+) DRG
[484A] VMR response (electromyography) to CRD with tenapanor and controls.
[484B] .
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